Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

By sjmartinez • June 3, 2024

White D, Schiller GJ, Madan S, Lentzsch S, Chubar E, Lavi N, Van Domelen DR, Bentur OS, Baljevic M. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Front Oncol. 2024 May 17;14:1352281. doi: 10.3389/fonc.2024.1352281. PMID: 38826786; PMCID: PMC11140414.

Tags: Hematology/Oncology, once weekly dose, optimal triplet combination, pomalidomide, Publications, relapsed/refractory multiple myeloma, selinexor

“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality

Sedrak MS, Ramalingam SS, Sparano JA. "Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality. Cancer. 2026 Jul 1;132(13):e70499.[...]

Case Report: A case of HIV seroconversion in a high-risk individual after 35 years of resistance with a CCR5DELTA32 heterozygous genotype

Aziz N, Kim EY, Jamieson BD, Mimiaga MJ, Martinez J, Detels R. Case Report: A case of HIV seroconversion in a high-risk individual after 35[...]

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer

Tsvetkova O, Gil TE, Kassir G, Castanon S, Kollapaneni SS, Han A, Park SJ, Li R, Velez MA, Lisberg AE. Evaluating datopotamab deruxtecan (Dato-DXd) as[...]